Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jan;61(1):116-121.
doi: 10.1002/mus.26742. Epub 2019 Nov 8.

Chaperones in sporadic inclusion body myositis-Validation of proteomic data

Anne-Katrin Güttsches  1 , Frank Jacobsen  1 , Anja Schreiner  1 , Janine Mertens-Rill  1 , Martin Tegenthoff  1 , Katrin Marcus  2 , Matthias Vorgerd  1 , Rudolf A Kley  1   3
Affiliations

Chaperones in sporadic inclusion body myositis-Validation of proteomic data

Anne-Katrin Güttsches et al. Muscle Nerve. 2020 Jan.

Abstract

Introduction: Sporadic inclusion body myositis (sIBM) is characterized by myopathological features including rimmed vacuoles (RVs) and proteins associated with protein aggregation, autophagy, and inflammation. Previous proteomic studies of RV areas revealed an overrepresentation of several chaperones and subunits of the T-complex protein 1 (TCP-1), which is involved in prevention of protein aggregation.

Methods: To validate our proteomic findings, immunofluorescence analyses of selected chaperones and quantitative Western blot analysis of TCP-1 proteins were performed in five sIBM patients and five healthy controls.

Results: Immunofluorescence studies confirmed increased immunoreactivity for VCP, UNC45B, GRP-75, αB-crystallin, LAMP-2, Rab-7a, and TCP-1α and TCP-θ in RVs. Quantitative Western blot analysis revealed a significantly higher level of TCP-1 in sIBM muscle tissue when compared with healthy controls.

Discussion: Our study findings validate new insights in protein quality control and degradation processes that seem to be relevant in sIBM. These data provide an important basis for future functional and therapeutic studies.

Keywords: T-complex protein 1; chaperones; inclusion body myositis; protein quality control; proteomics; quantitative Western blot analysis.

PubMed Disclaimer

References

REFERENCES

    1. Keller CW, Schmidt J, Lünemann JD. Immune and myodegenerative pathomechanisms in inclusion body myositis. Ann Clin Transl Neurol. 2017;4:422-445.
    1. Machado PM, Dimachkie MM, Barohn RJ. Sporadic inclusion body myositis: new insights and potential therapy. Curr Opin Neurol. 2014;27:591-598.
    1. Rose MR. 188th ENMC International Workshop: Inclusion Body Myositis, 2-4 December 2011, Naarden, The Netherlands. Neuromuscul Disord. 2013;23:1044-1055.
    1. Güttsches A-K, Brady S, Krause K, et al. Proteomics of rimmed vacuoles define new risk allele in inclusion body myositis. Ann Neurol. 2017;81:227-239.
    1. Brady S, Squier W, Sewry C, Hanna M, Hilton-Jones D, Holton JL. A retrospective cohort study identifying the principal pathological features useful in the diagnosis of inclusion body myositis. BMJ Open. 2014;4:e004552.

Publication types

Substances

LinkOut - more resources